HomeCompareAYLA vs CL

AYLA vs CL: Dividend Comparison 2026

AYLA yields 374.60% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AYLA wins by $7105.54M in total portfolio value
10 years
AYLA
AYLA
● Live price
374.60%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7105.58M
Annual income
$4,658,993,972.92
Full AYLA calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — AYLA vs CL

📍 AYLA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAYLACL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AYLA + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AYLA pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AYLA
Annual income on $10K today (after 15% tax)
$31,841.17/yr
After 10yr DRIP, annual income (after tax)
$3,960,144,876.98/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, AYLA beats the other by $3,960,140,285.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AYLA + CL for your $10,000?

AYLA: 50%CL: 50%
100% CL50/50100% AYLA
Portfolio after 10yr
$3552.81M
Annual income
$2,329,499,687.44/yr
Blended yield
65.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

AYLA
Analyst Ratings
6
Buy
2
Hold
1
Sell
Consensus: Buy
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AYLA buys
0
CL buys
0
No recent congressional trades found for AYLA or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAYLACL
Forward yield374.60%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$7105.58M$40.8K
Annual income after 10y$4,658,993,972.92$5,401.96
Total dividends collected$6876.29M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: AYLA vs CL ($10,000, DRIP)

YearAYLA PortfolioAYLA Income/yrCL PortfolioCL Income/yrGap
1← crossover$48,160$37,460.20$11,012$312.01+$37.1KAYLA
2$220,138$168,606.60$12,196$412.95+$207.9KAYLA
3$955,821$720,273.70$13,599$549.66+$942.2KAYLA
4$3,945,504$2,922,775.63$15,288$736.64+$3.93MAYLA
5$15,497,234$11,275,544.08$17,353$995.28+$15.48MAYLA
6$57,972,988$41,390,948.05$19,926$1,357.80+$57.95MAYLA
7$206,739,282$144,708,184.88$23,194$1,873.82+$206.72MAYLA
8$703,499,231$482,288,199.06$27,439$2,621.52+$703.47MAYLA
9$2,286,525,626$1,533,781,448.26$33,088$3,727.38+$2286.49MAYLA
10$7,105,576,392$4,658,993,972.92$40,806$5,401.96+$7105.54MAYLA

AYLA vs CL: Complete Analysis 2026

AYLAStock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Full AYLA Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this AYLA vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AYLA vs SCHDAYLA vs JEPIAYLA vs OAYLA vs KOAYLA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.